US-Mexico Trade Agreement Elicits Another Battle Over Biologics Data Exclusivity
Executive Summary
Agreement in principle between US and Mexico would establish 10 years of data protection for biologic drugs, which AAM opposes.
You may also be interested in...
US-Mexico-Canada Trade Agreement Sets 10-Year Floor For Biologics Market Exclusivity
USA's 12-year-plus scheme won't change, but Canada and Mexico must offer sponsors more than previously; biosimilar industry bemoans lack of incentives for competition. Trade pact also specifies damages award options and links regulatory review to patent disputes.
US-Mexico-Canada Trade Agreement Sets 10-Year Floor For Biologics Market Exclusivity
USA's 12-year-plus scheme won't change, but Canada and Mexico must offer sponsors more than previously; biosimilar industry bemoans lack of incentives for competition. Trade pact also specifies damages award options and links regulatory review to patent disputes.
Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.